NYSEAMERICAN:AST - Asterias Biotherapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.26 -0.04 (-3.08 %)
(As of 11/18/2018 01:18 PM ET)
Previous Close$1.26
Today's Range$1.2302 - $1.30
52-Week Range$0.76 - $2.65
Volume88,829 shs
Average Volume205,988 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Receive AST News and Ratings via Email

Sign-up to receive the latest news and ratings for AST and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:AST
Previous SymbolNYSEMKT:AST
CUSIPN/A
Phone+1-510-4563805

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees31
Outstanding Shares55,660,000
Market Cap$0.00
OptionableOptionable

Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions

What is Asterias Biotherapeutics' stock symbol?

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.81 million. View Asterias Biotherapeutics' Earnings History.

When is Asterias Biotherapeutics' next earnings date?

Asterias Biotherapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Asterias Biotherapeutics.

What price target have analysts set for AST?

3 equities research analysts have issued twelve-month price objectives for Asterias Biotherapeutics' shares. Their predictions range from $6.00 to $11.00. On average, they expect Asterias Biotherapeutics' share price to reach $8.50 in the next year. This suggests a possible upside of 574.6% from the stock's current price. View Analyst Price Targets for Asterias Biotherapeutics.

What is the consensus analysts' recommendation for Asterias Biotherapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Asterias Biotherapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Asterias Biotherapeutics.

What are Wall Street analysts saying about Asterias Biotherapeutics stock?

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (11/15/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We use a sum-of- the-parts approach, which ascribes a $440M risk-adjusted net present value (rNPV) to the AST-OPC1 program in AST-VAC programs in NSCLC and prostate cancer." (9/5/2018)

Has Asterias Biotherapeutics been receiving favorable news coverage?

News articles about AST stock have been trending very positive this week, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Asterias Biotherapeutics earned a daily sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future.

Are investors shorting Asterias Biotherapeutics?

Asterias Biotherapeutics saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 3,488,289 shares, a drop of 6.2% from the October 15th total of 3,719,008 shares. Based on an average daily volume of 271,482 shares, the days-to-cover ratio is presently 12.8 days. Approximately 10.5% of the company's stock are short sold. View Asterias Biotherapeutics' Current Options Chain.

Who are some of Asterias Biotherapeutics' key competitors?

Who are Asterias Biotherapeutics' key executives?

Asterias Biotherapeutics' management team includes the folowing people:
  • Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
  • Dr. Edward D. Wirth III, Chief Medical Officer (Age 53)
  • Dr. Katharine E. Spink, Consultant (Age 44)
  • Mr. Stephen L. Cartt, Advisor & Director (Age 55)
  • Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)

Who are Asterias Biotherapeutics' major shareholders?

Asterias Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.34%). Company insiders that own Asterias Biotherapeutics stock include Edward Wirth, Katharine E Spink and Michael H Mulroy. View Institutional Ownership Trends for Asterias Biotherapeutics.

Which major investors are buying Asterias Biotherapeutics stock?

AST stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Asterias Biotherapeutics.

How do I buy shares of Asterias Biotherapeutics?

Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Asterias Biotherapeutics' stock price today?

One share of AST stock can currently be purchased for approximately $1.26.

What is Asterias Biotherapeutics' official website?

The official website for Asterias Biotherapeutics is http://asteriasbiotherapeutics.com.

How can I contact Asterias Biotherapeutics?

Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.


MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  212
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel